Cilostazol CR is under clinical development by Genovate Biotechnology and currently in Phase I for Intermittent Claudication. According to GlobalData, Phase I drugs for Intermittent Claudication does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Cilostazol CR LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Cilostazol CR overview
Cilostazol CR (PMR) is under development for the treatment of intermittent claudication. The drug candidate is a controlled release formulation of cilostazol. It acts by targeting phosphodiesterase 3 (PDE3).
Genovate Biotechnology overview
Genovate Biotechnology (GBL) is a pharmaceutical preparation manufacturing company. It research and develops small molecule drugs. The company offers cardiovascular system drugs, external use products, musculoskeletal system drugs, anti-infective agents, immunological preparation, anticancer drugs, antiviral drug, and respiratory drugs. GBL also offers urogenital drugs, gastrointestinal drugs, disability medicine, hypnotics, antidisease drug, anti-anxiety agent and antiepileptics. The company provides new drug and new formulation development, cGMP drug manufacturing, product registration, clinical trials, drug marketing and distribution. GBL carters its products under the brands Genetaxyl, Genazole, Angidil, Felopine-SR and others. Its on-going development project centres on therapeutic agents for the elderly diseases. It has operations throughout Taiwan. GBL is headquartered in Hukou, Taiwan.
For a complete picture of Cilostazol CR’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
